BHVN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	3.22M
Average Volume	1.27M
Market Cap	3.18B
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-1.500 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.80
ATR14	$0.191 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Childs John W	Buy	2 091	Common Shares
2024-04-05	Coric Vlad	Buy	232	Common Shares
2024-04-05	Coric Vlad	Buy	231	Common Shares
2024-04-05	Coric Vlad	Buy	231	Common Shares
2024-03-08	Childs John W	Buy	19 412	Common Shares

INSIDER POWER
96.45
Last 99 transactions
Buy: 15 011 404 \| Sell: 296 589

Volume Correlation

Long: 0.08 (neutral)

Short: 0.30 (neutral)

Signal:(59.384) Neutral

Biohaven Pharmaceutical Correlation

10 Most Positive Correlations
THD	0.906
KB	0.888
SHG	0.882
NUVB	0.877
BKF	0.871
MX	0.866
YINN	0.866
RAYC	0.862
HBI	0.859
EDC	0.858

10 Most Negative Correlations
CMO	-0.872
CSLT	-0.808

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biohaven Pharmaceutical Correlation - Currency/Commodity

-0.30
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.39
( neutral )

0.84
( strong )

-0.78
( moderate negative )

Biohaven Pharmaceutical Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.37M (0.00 %)
EPS:	$-5.73

Q4	2023
Revenue:	$0
Gross Profit:	$-948 000 (0.00 %)
EPS:	$-1.810

Q3	2023
Revenue:	$0
Gross Profit:	$-857 000 (0.00 %)
EPS:	$-1.500

Q2	2023
Revenue:	$0
Gross Profit:	$-800 000 (0.00 %)
EPS:	$-1.320

Financial Reports:

No articles found.

Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.